Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

BACKGROUND: A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV(1)) time profile after 3 weeks’ treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily dose) versus placebo deli...

Descripción completa

Detalles Bibliográficos
Autores principales: Beeh, Kai-Michael, LaForce, Craig, Gahlemann, Martina, Wenz, Arne, Toorawa, Robert, Fležar, Matjaž
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509767/
https://www.ncbi.nlm.nih.gov/pubmed/26177937
http://dx.doi.org/10.1186/s12931-015-0243-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509767/
https://www.ncbi.nlm.nih.gov/pubmed/26177937
http://dx.doi.org/10.1186/s12931-015-0243-1

Ejemplares similares